24 September 2014, London, UK: Instinctif Partners (formerly College Hill) sponsored & hosted a breakfast briefing with Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK, entitled “Innovative approaches to better diagnose and treat cancer patients: analysis of blood borne tumour cells and DNA” on 23 September 2014.
There is a pressing need to improve methods used to assess cancer diagnosis and treatment especially in light of the recent demonstration that tumours are heterogeneous genetically. Multiple direct biopsies, either from different sites or over time (or both), are difficult to achieve for many reasons. The discoveries that in the blood of cancer patients both circulating tumour cells (CTCs) and cell-free tumour DNA (cfDNA) can be detected offers new ‘non-invasive’ methods to determine the true genetic make-up of a cancer, its likelihood of spreading and its response to therapy during a course of treatment. Overall, both CTCs and cfDNA show the potential for improving drug development including in immunotherapy, an area which is demonstrating how cancer research is improving patient outcomes.
The breakfast briefing was chaired by CRT Chief Scientific Officer Dr Clive Stanway, and included discussions on these innovative developments by leading Cancer Research UK-funded scientists Professor Carlos Caldas, Dr Nitzan Rosenfeld, and Professor Caroline Dive. The event attended by key journalists from the industry provided an excellent opportunity for media exposure to this rapidly evolving field.
Dr Clive Stanway, CRT Chief Scientific Officer explained: “This event really helped us demonstrate the potential of analysing circulating tumour cells (CTCs) and cell-free tumour DNA (cfDNA), two new technologies for cancer patient treatment and drug discovery. The Instinctif Partners team was instrumental in helping us getting this message across, the planning and execution of the event went very smoothly and it has been great to work with the team.”
Commenting on Instinctif Partner’s sponsorship of the event, Dr Christelle Kerouedan, Associate Partner, added: "Using our extensive experience and resources in media event planning and execution, Instinctif has helped Cancer Research Technology to highlight this rapidly evolving field of cancer research to key journalists. We are delighted to have worked with the CRT team on the organisation of this successful event”.
For Further Information:
Dr Christelle Kerouedan
Associate Partner, Life Sciences
+44 (0)20 7457 2020
About Cancer Research Technology
Cancer Research Technology Limited (CRT) is a specialist commercialisation and development company, which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. CRT is wholly owned by Cancer Research UK, the world’s leading cancer charity dedicated to saving lives through research.
About Instinctif Partners
Instinctif Partners is a leading international business communications consultancy. Its Life Sciences team is unique in that it has expertise across financial, corporate, healthcare and marketing communications, and integrates design into its communications mix. The Life Sciences team also offers seamless global outreach with teams located in the UK, Germany, Australia and the US. Its client base spans pharma, biotechnology, medical devices, diagnostics, healthcare, laboratory supply and service providers in addition to venture capitalists, recruitment companies, not-for-profit, academic organisations and science-associated bodies.
Dr Christelle Kerouedan